Abstract

Hypercholesterolemia is an insidious disease and the leading factor to the deadliest killer in the United States – cardiovascular disease (Centers for Disease Control and Prevention, 2023a). Over 85 million American adults suffer from elevated cholesterol, and treatment can prove challenging and may require multiple modalities outside just pharmaceutical intervention – such as dietary and other lifestyle changes (Centers for Disease Control and Prevention, 2023b; Goldman, 2023). Green tea – among the most common teas consumed worldwide – exerts a uniquely antihyperlipidemic and cardioprotective effect that suggests its consideration as a potentially-viable nonpharmacological option for hypercholesterolemia (Harvard Health Publishing, 2012; Kosugi, n.d.). Green tea is rich in catechin phytochemicals that inhibit production of low-density lipoprotein (LDL) – considered by most medical professionals as the worst cholesterol for cardiovascular health (Cao et al., 2019; Cui et al., 2020). These excellent qualities in conjunction with relatively miniscule risks of adverse effects make a strong case for implementing the following proposed benchmark project: A 10-week, clinic-based pilot program of green tea supplementation for patients newly-diagnosed with hypercholesterolemia. This project is an investment in the future of the community – it will safely promote the cardiac health of patients whilst nurturing beneficial ties to local businesses.

Date of publication

Fall 12-4-2023

Document Type

MSN Capstone Project

Language

english

Persistent identifier

http://hdl.handle.net/10950/4511

Degree

Master of Science in Nursing

Download

Share

COinS